NPJ VaccinesPub Date : 2026-10-14DOI: 10.1038/s41541-026-01606-6
Jia Liu, Longping Chen, Dan Li, Zhuo Wang, Bo Wang, Chun Peng, Long Ma, Yongqiang Zhao, Yating Wang, Tiegang Bai, Dongni Yang, Enqi Du
{"title":"A structure-guided trivalent subunit vaccine confers maternal protection to neonatal piglets against PEDV and PDCoV.","authors":"Jia Liu, Longping Chen, Dan Li, Zhuo Wang, Bo Wang, Chun Peng, Long Ma, Yongqiang Zhao, Yating Wang, Tiegang Bai, Dongni Yang, Enqi Du","doi":"10.1038/s41541-026-01606-6","DOIUrl":"10.1038/s41541-026-01606-6","url":null,"abstract":"<p><p>Antigenic divergence among porcine epidemic diarrhea virus (PEDV) genotypes and porcine deltacoronavirus (PDCoV) limits the cross-protection provided by current commercial vaccines. Here, employing a structure-guided antigen design strategy, we developed a trivalent subunit vaccine concurrently targeting PEDV G2a, PEDV G2b, and PDCoV. The vaccine antigen set comprises optimized spike ectodomain antigens, featuring stabilizing mutations, a heptad repeat 2 (HR2) deletion, a fused neutralizing epitope, and a flagellin adjuvant fused to the N-terminus. Formulated with MF59+CpG adjuvants, this trivalent vaccine elicited robust PEDV- and PDCoV-specific neutralizing antibody responses and Th1/Th2-associated cellular immune responses characterized by IFN-γ, IL-2, and IL-4 production in mice. Immunization of pregnant sows with 300 μg dose induced high-titer IgG, IgA, and colostral secretory IgA (SIgA) against all three target viruses. Although neutralizing antibody titers were comparable between the 100 μg and 300 μg dose groups, the 300 μg group showed higher and more persistent levels of colostral binding IgG and SIgA. Following maternal immunization, piglets that acquired maternal antibodies through colostrum exhibited reduced clinical diarrhea, lower fecal viral RNA shedding, and less severe intestinal lesions after challenge with PEDV G2a, PEDV G2b, or PDCoV. These findings support this structure-guided trivalent subunit vaccine as a promising candidate for maternal immunization against co-circulating porcine enteric coronaviruses.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"11 1","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13752287/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149387341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ VaccinesPub Date : 2026-10-11DOI: 10.1038/s41541-026-01607-5
Alberto Cagigi, Annette Kraus, T Anh Wartel, Andrew Steer, Jonathan Carapetis, Alma Fulurija, Jerome H Kim
{"title":"A staged clinical development and evidence-generation framework for Group A Streptococcus vaccines.","authors":"Alberto Cagigi, Annette Kraus, T Anh Wartel, Andrew Steer, Jonathan Carapetis, Alma Fulurija, Jerome H Kim","doi":"10.1038/s41541-026-01607-5","DOIUrl":"10.1038/s41541-026-01607-5","url":null,"abstract":"<p><p>Group A Streptococcus (Strep A) causes substantial global morbidity and mortality, yet vaccine development faces scientific, regulatory, and strategic challenges. We propose a platform-agnostic, staged clinical development and evidence-generation framework aligning trial feasibility with public health priorities. Laboratory-confirmed symptomatic pharyngitis could provide a feasible pivotal efficacy endpoint for initial licensure, subject to regulatory agreement. Complementary efficacy, effectiveness, and implementation studies could then generate evidence across diverse populations and outcomes.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"11 1","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13655178/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149167385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ VaccinesPub Date : 2026-10-01DOI: 10.1038/s41541-026-01596-5
José Tuells, Stanley A Plotkin
{"title":"The smallpox ghost in Voltaire's life: inoculation and the origins of vaccine acceptance.","authors":"José Tuells, Stanley A Plotkin","doi":"10.1038/s41541-026-01596-5","DOIUrl":"https://doi.org/10.1038/s41541-026-01596-5","url":null,"abstract":"<p><p>Smallpox shaped eighteenth-century debates on risk, trust, and prevention. Voltaire, marked by the disease throughout his life-the \"smallpox ghost\"-emerged as a prominent advocate of smallpox inoculation (variolation), a preventive practice that preceded Jennerian vaccination by several decades. Through his writings, he framed the practice as a conflict between empirical reasoning and social resistance. This Perspective examines his role in the early acceptance of preventive medicine and highlights its relevance for understanding contemporary challenges in vaccine acceptance.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"11 1","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13631265/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149112837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ VaccinesPub Date : 2026-09-04DOI: 10.1038/s41541-026-01573-y
Nicole Moor, Nianzhen Chen, Georg M N Behrens, Lu Zhang, Anna-Sophie Moldenhauer, Michael Winkler, Christine Happle, Sandra Steffens, Metodi V Stankov, Karsten Lürken, Stefan Pöhlmann, Markus Hoffmann
{"title":"Host cell entry and neutralisation sensitivity of H3N2 influenza A virus subclade K.","authors":"Nicole Moor, Nianzhen Chen, Georg M N Behrens, Lu Zhang, Anna-Sophie Moldenhauer, Michael Winkler, Christine Happle, Sandra Steffens, Metodi V Stankov, Karsten Lürken, Stefan Pöhlmann, Markus Hoffmann","doi":"10.1038/s41541-026-01573-y","DOIUrl":"10.1038/s41541-026-01573-y","url":null,"abstract":"<p><p>In 2025, a mutated H3N2 lineage, subclade K, emerged, showing high activity in many regions. Mutations in the hemagglutinin (HA) may affect cell entry and antibody-mediated neutralisation. Using pseudovirus particles, we show that subclade K-HA drives augmented entry into certain cell lines and displays significant antibody evasion. Both phenotypes were linked to mutation A186D. Influenza vaccination significantly boosted H3N2 subclade K neutralisation, suggesting that current vaccines may provide considerable protection.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"11 1","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13545212/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148891839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ VaccinesPub Date : 2026-09-02DOI: 10.1038/s41541-026-01548-z
Samuel Asri, Paraskevi C Fragkou, Elena Ahrens, Svenja S Hartmann, Clemens Thölken, Chrysanthi Skevaki
{"title":"Immunogenicity and safety of seasonal influenza vaccine co-administered with other vaccines: a systematic review and meta-analysis.","authors":"Samuel Asri, Paraskevi C Fragkou, Elena Ahrens, Svenja S Hartmann, Clemens Thölken, Chrysanthi Skevaki","doi":"10.1038/s41541-026-01548-z","DOIUrl":"10.1038/s41541-026-01548-z","url":null,"abstract":"<p><p>Seasonal influenza remains a leading cause of global morbidity and mortality, highlighting the need for vaccination strategies that improve coverage and streamline vaccine delivery. In this systematic review and meta-analysis, we searched PubMed, Embase, Web of Science, Scopus, and the Cochrane Central Register of Controlled Trials for randomised controlled trials (RCTs), cohort, case-control, and cross-sectional studies, evaluating immunogenicity and safety of same-day co-administration of influenza vaccines with COVID-19 or other vaccines, compared with non-concomitant administration. Comparators included sequential administration, single vaccine administration or placebo-controlled delayed vaccination. Risk of bias was evaluated using the Cochrane Risk-of-Bias tool for Randomized Trials and Risk of Bias In Non-randomized Studies of Interventions; certainty of evidence was evaluated using Grading of Recommendations, Assessment, Development and Evaluation. Immunogenicity was assessed using geometric mean fold rise (GMFR) in antibody titres and seroprotection rate. Safety was assessed by adverse event (AE) incidence. 52 eligible studies were included. Influenza immunogenicity was comparable between the co-administration and non-concomitant comparator group across all strains (H1N1 GMFR ratio of means (ROM): 1.02 [95% CI: 0.95-1.10]; H3N2, 1.05 [95% CI: 0.97-1.13]; B strain, 1.01 [95% CI: 0.97-1.05]). Pooled risk ratio (RR) for seroprotection was 1.00 for all three strains with 95% CIs ranging from 0.99-1.01. GMFR for COVID-19 vaccines was modestly reduced under co-administration (ROM 0.84 [95% CI: 0.74-0.95]; p = 0.006). Serious AEs were more frequent in the co-administration group compared to the non-concomitant group (RR 1.41 [95% CI: 1.07-1.86]; p = 0.014; absolute risk difference: 1.56 percentage points). Overall, co-administration preserves influenza immunogenicity but modestly reduces COVID-19 vaccine GMFR. Although safety findings warrant cautious interpretation, the low absolute risk difference supports its feasibility as a strategy to streamline vaccination schedules and improve uptake.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"11 1","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13728179/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149323376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Vaccine acceptance in a future pandemic after COVID-19 and its decision drivers in Japan.","authors":"Junna Kawasaki, Masakaze Hamada, Masaki Machida, Ryo Komorizono, Mie Kobayashi-Ishihara, Naoko Fujita, Takahiro Tabuchi, Yuki Furuse","doi":"10.1038/s41541-026-01561-2","DOIUrl":"10.1038/s41541-026-01561-2","url":null,"abstract":"<p><p>Vaccine hesitancy has long been recognized as a global health concern and has become an even greater challenge during and after the COVID-19 pandemic. Although extensive research has examined hesitancy toward COVID-19, how the general population would respond to vaccination in a future pandemic remains unclear. Furthermore, little is known about the conditions that may reduce hesitancy. In this study, we conducted a nationwide internet survey in Japan in 2024-2025 involving 28,000 participants to assess vaccination intentions in a hypothetical future pandemic, identify factors associated with vaccine hesitancy, and examine conditions that may increase willingness to be vaccinated. We analyzed associations between individual characteristics and vaccination intention using logistic regression and explored heterogeneity in prioritized factors to determine vaccination intention using unsupervised clustering analysis. We found that only 53.1% of respondents reported intending to be vaccinated in a future pandemic-a marked decline from observed COVID-19 vaccination coverage. Notably, 35.8% of individuals who were vaccinated during the COVID-19 pandemic expressed hesitancy. Vaccination intention was lower among adults aged 20-40 years, women, individuals with lower income or educational attainment, and those endorsing misinformation or conspiracy statements. Cluster analysis identified eight distinct groups with heterogeneous priority structures. Free vaccination and evidence from clinical trials were prioritized across all clusters, whereas the prioritization of trust in authorities, social influence, domestic vaccine production, and convenience varied substantially across clusters. Public intentions to vaccinate in a future pandemic are shaped by diverse perspectives and values. Tailored strategies and risk communication approaches that address these heterogeneous concerns may be critical to strengthening preparedness for future pandemics.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"11 1","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13529798/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148866090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ VaccinesPub Date : 2026-08-19DOI: 10.1038/s41541-026-01556-z
M Mugica-Unamuno, E Molina, M Oyanguren, P Mendívil, M Fernández, M V Geijo, R Arrazuria, J M Garrido, N Elguezabal
{"title":"Paratuberculosis vaccination induces a phenotype consistent with trained immunity in bovine neutrophils.","authors":"M Mugica-Unamuno, E Molina, M Oyanguren, P Mendívil, M Fernández, M V Geijo, R Arrazuria, J M Garrido, N Elguezabal","doi":"10.1038/s41541-026-01556-z","DOIUrl":"10.1038/s41541-026-01556-z","url":null,"abstract":"<p><p>Vaccination decreases bacterial shedding and reduces the incidence and severity of infection by Mycobacterium avium subsp. paratuberculosis (Map), the causative agent of paratuberculosis (PTB), a chronic granulomatous enteritis that economically impacts the dairy industry. An inactivated Map vaccine exhibits features suggestive of trained immunity in cattle, along with enhanced neutrophil (PMN) activation in rabbits. Although PMNs from healthy cattle exhibit antimicrobial effects against Map, the impact of vaccination on bovine PMN function remains undetermined. This study has further explored the mechanisms of trained immunity mediated by PMNs elicited by this vaccine in calves. PMN mediated phagocytosis, ROS production and NET release showed a significant increase in vaccinated calves upon stimulation in ex vivo assays. Furthermore, PMNs from vaccinated animals exhibited decreased motility that was partially restored upon ex vivo stimulation with Map. Upregulation of phagocytosis receptors such as TREM2 and PBDL1, genes related to NETosis TREM2, LYZ and F13A1 and downregulation of genes involved in chemotaxis, adhesion, and motility in vaccinated animals support these findings. Altogether, the data indicate that this inactivated Map vaccine induces changes consistent with trained immunity in calves.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"11 1","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13594100/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149017707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ VaccinesPub Date : 2026-08-18DOI: 10.1038/s41541-026-01549-y
Swayam Prakash, Nisha R Dhanushkodi, Afshana Quadiri, Hawa Vahed, Aziz A Chentoufi, Pierre-Gregoire Coulon, Izabela Coimbra Ibraim, Assia El Babsiri, Delia F Tifrea, Cesar J Figueroa, Daniel Gil, Jeffrey B Ulmer, Lbachir BenMohamed
{"title":"Multi-antigen coronavirus vaccine induces potent and durable cross-protection against multiple SARS-CoV-2 variants.","authors":"Swayam Prakash, Nisha R Dhanushkodi, Afshana Quadiri, Hawa Vahed, Aziz A Chentoufi, Pierre-Gregoire Coulon, Izabela Coimbra Ibraim, Assia El Babsiri, Delia F Tifrea, Cesar J Figueroa, Daniel Gil, Jeffrey B Ulmer, Lbachir BenMohamed","doi":"10.1038/s41541-026-01549-y","DOIUrl":"10.1038/s41541-026-01549-y","url":null,"abstract":"<p><p>The first-generation Spike-based COVID-19 vaccines reduced the risk of hospitalization, serious illness, and death from SARS-CoV-2 infections. However, waning immunity failed to prevent immune escape, resulting in multiple variants of concern (VOCs) and prolonging the pandemic. We hypothesize that next-generation CoV vaccines incorporating highly conserved SARS-CoV-2 T cell antigens would confer potent, broad, long-lasting cross-protective immunity against multiple VOCs. In this study, we identified 10 non-Spike antigens common and highly conserved across 8.7 million SARS-CoV-2 strains, prior VOCs, SARS-CoV-1, MERS-CoV, seasonal human cold CoVs, and animal CoVs. Seven antigens were preferentially recognized by CD8<sup>+</sup> and CD4<sup>+</sup> T cells from unvaccinated asymptomatic COVID-19 patients, irrespective of VOC. Three conserved antigens (NSP2, NSP14, Nucleoprotein) administered to golden Syrian hamsters: (i) induced high frequencies of lung-resident polyfunctional CXCR5<sup>+</sup>CD4<sup>+</sup> T<sub>FH</sub> cells, GzmB<sup>+</sup>CD4<sup>+</sup>/CD8<sup>+</sup> cytotoxic T cells, and CD69<sup>+</sup>IFN-γ<sup>+</sup>TNFα<sup>+</sup>CD4<sup>+</sup>/CD8<sup>+</sup> effector T cells; (ii) reduced morbidity, viral load, lung pathology, and COVID-19-like symptoms from various VOCs, including the pathogenic B.1.617.2 Delta and the recent KP.3 Omicron variants; (iii) improved protection conferred by spike-alone mRNA; and (iv) conferred protection that lasted for more than 1 year. This multi-antigen CoV vaccine could provide potent, broad-spectrum, and durable cross-protective immunity against current and future variants of concern in the clinic.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"11 1","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13638991/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149112862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ VaccinesPub Date : 2026-08-14DOI: 10.1038/s41541-026-01552-3
Alan D T Barrett, Richard E Rupp, Richard W Titball, Veronika von Messling
{"title":"Vaccinology in the twenty-first century revisited.","authors":"Alan D T Barrett, Richard E Rupp, Richard W Titball, Veronika von Messling","doi":"10.1038/s41541-026-01552-3","DOIUrl":"https://doi.org/10.1038/s41541-026-01552-3","url":null,"abstract":"","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"11 1","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13476269/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148760080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}